In addition to its exertion in melanoma and renal cell carcinoma, the potential of IL-2 for performing cancer immunotherapy in other solid tumors, such as colorectal and non-small cell lung cancer (NSCLC), was investigated and achieved encouraging outcomes (3, 76). Here, IL2 is linked to non-small cell lung carcinoma.